InvestorsHub Logo
Followers 36
Posts 1166
Boards Moderated 0
Alias Born 03/07/2013

Re: None

Tuesday, 09/20/2016 2:13:56 PM

Tuesday, September 20, 2016 2:13:56 PM

Post# of 118392
From my notes on Landers 2016 Overview letter, RGBP has accomplished most of the things outlined by Landers for 2016 so far with the main exception of beginning of HemaXellerate clinical trial which was expected for Q3 or by end of this month.

Not everything happened within their projected timeline, but the following has occurred in 2016:

1. They announced partnerships/collaboration with NIH/NCATS, Eli Lilly and Comell Univ
2.IND response to dCellVax (happened in Q3 instead of Q2)
3. Initial IND for inhibition of NR2F6 (Did this happen? Certainly a lot of development in this area, with patents filed and compounds developed, but I don't think an official IND yet)
4. Begin HemaXellerate trial Q3 (not done, awaiting news)
5. Identify small molecule inhibitor of NR2F6 (Q3) done, seems they have identified 3 compounds that need further development.

How big will the T-trades be at end of day today? I'm guessing over 100,000. Looking for more money coming in tomorrow to wipe out today's wash.